<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571763</url>
  </required_header>
  <id_info>
    <org_study_id>k(2017)33</org_study_id>
    <nct_id>NCT03571763</nct_id>
  </id_info>
  <brief_title>The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients</brief_title>
  <official_title>The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients: Prospective, Multi-center, Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective cohort study is to investigate whether antithrombotic therapy
      in the secondary prevention of ischemic stroke increases the risk of the emerging CMBs and
      whether the change is associated with an increased risk of intracranial hemorrhage, providing
      an imaging evidence for individualized antithrombotic therapy in such patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral microbleeds（CMBs） is a subclinical lesion caused by microvascular disease in the
      brain, characterized by microleakage of blood. About 30% of ischemic stroke patients, 40% of
      the healthy people over 80 years old, and 60% of intracranial hemorrhage patients have
      microbleeds. With the development of imaging technology, clinically more and more patients
      have found microbleeds in the brain. How these patients are treated with antithrombotic drugs
      is not yet clear and is in urgent need of evidence. There are only a few prospective cohort
      studies to determine whether antithrombotic therapy increases the risk of intracranial
      hemorrhage in ischemic stroke patients with CMBs, but the results are uncertain. More
      importantly, whether antithrombotic therapy increases the incidence of the emerging CMBs, and
      whether the change of increased microbleeds is associated with increased intracranial
      hemorrhage has not been reported.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>all cerebral bleeding events</measure>
    <time_frame>180 days</time_frame>
    <description>incidence of both cerebral microbleeds and intracranial hemorrhage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>neurological function outcome</measure>
    <time_frame>180 days</time_frame>
    <description>proportion of mRS 0-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral microbleeds</measure>
    <time_frame>180 days</time_frame>
    <description>proportion of cerebral microbleeds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral hemorrhage</measure>
    <time_frame>180 days</time_frame>
    <description>proportion of cerebral hemorrhage</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1875</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>acute ischemic stroke patient</arm_group_label>
    <description>acute ischemic stroke patient acute ischemic stroke patient Patient age ≥18 years .Acute ischemic stroke patient confirmed by imaging(SWI sequence) .Time of onset: within 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SWI sequence</intervention_name>
    <description>Acute ischemic stroke patient confirmed by SWI sequence</description>
    <arm_group_label>acute ischemic stroke patient</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ischemic stroke patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient age ≥18 years;

          2. Acute ischemic stroke patient confirmed by imaging;

          3. Time of onset: within 3 months;

          4. Baseline SWI sequence is completed before starting the secondary prevention of
             ischemic stroke;

          5. Baseline SWI sequence must have at least one CMB ;

          6. NIHSS≤10

        Exclusion Criteria:

          1. MRI contraindication;

          2. Hemorrhagic transformation after acute Ischemic stroke;

          3. Contraindication for antiplatelet or anticoagulation therapy;

          4. Severe head trauma or intracranial hemorrhage occurred in the past six months;

          5. obvious coagulopathy;

          6. Other intracranial lesions associated with (such as tumor, cerebral vascular
             malformation);

          7. other unqualified patients judged by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chen huisheng, doctor</last_name>
    <role>Study Director</role>
    <affiliation>General Hospital of Shenyang Military Region</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>chen huisheng, doctor</last_name>
    <phone>86-24-28897511</phone>
    <email>chszh@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>wang xinhong, doctor</last_name>
    <phone>15309885658</phone>
    <email>450341972@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital of ShenYang Military Region</name>
      <address>
        <city>ShenYang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Xia, Ph.D</last_name>
      <email>xiacheng1975@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Director of neurological department</investigator_title>
  </responsible_party>
  <keyword>Cerebral Hemorrhage</keyword>
  <keyword>anti-thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

